Terms: = Ovarian cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
203 results:
1. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathologic Analysis and Molecular Profiling of ovarian Steroid Cell Tumors.
Mendoza RP; Wang P; Smith HL; Fitzpatrick CA; Haridas R; Wanjari P; Briese R; Shahid A; McCluggage WG; Bennett JA
Am J Surg Pathol; 2023 Dec; 47(12):1398-1408. PubMed ID: 37796179
[TBL] [Abstract] [Full Text] [Related]
3. Synthesis, characterization, and biological properties of novel Schiff bases containing pentafluorophenyl hydrazine.
Hamurcu F
J Biochem Mol Toxicol; 2023 Dec; 37(12):e23512. PubMed ID: 37638565
[TBL] [Abstract] [Full Text] [Related]
4. Identification of mdm2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
Zheng J; Miao F; Wang Z; Ma Y; Lin Z; Chen Y; Kong X; Wang Y; Zhuang A; Wu T; Li W
Life Sci; 2023 Aug; 327():121832. PubMed ID: 37276911
[TBL] [Abstract] [Full Text] [Related]
5. Optimized spirooxindole-pyrazole hybrids targeting the p53-mdm2 interplay induce apoptosis and synergize with doxorubicin in A549 cells.
Islam MS; Al-Majid AM; Sholkamy EN; Barakat A; Viale M; Menichini P; Speciale A; Loiacono F; Azam M; Verma VP; Yousuf S; Teleb M
Sci Rep; 2023 May; 13(1):7441. PubMed ID: 37156796
[TBL] [Abstract] [Full Text] [Related]
6. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract] [Full Text] [Related]
7. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract] [Full Text] [Related]
8. The risk of cancer in patients with primary Sjögren syndrome: a single-center study from Turkey.
Aslan B; Öğüt TS; Erbasan F; Dilbil M; Çelik E; Terzioğlu ME; Yazısız V
Turk J Med Sci; 2022 Jun; 52(3):587-595. PubMed ID: 36326315
[TBL] [Abstract] [Full Text] [Related]
9. p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar S; Tchounwou PB
J Cell Mol Med; 2022 Sep; 26(17):4727-4739. PubMed ID: 35946055
[TBL] [Abstract] [Full Text] [Related]
10. Enhancement of mdm2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.
Alzahrani A; Natarajan U; Rathinavelu A
Cancer Genet; 2022 Aug; 266-267():57-68. PubMed ID: 35785714
[TBL] [Abstract] [Full Text] [Related]
11. Survivin, sonic hedgehog, krüppel-like factors, and p53 pathway in serous ovarian cancer: an immunohistochemical study.
Londero AP; Orsaria M; Viola L; Marzinotto S; Bertozzi S; Galvano E; Andreetta C; Mariuzzi L
Hum Pathol; 2022 Sep; 127():92-101. PubMed ID: 35777700
[TBL] [Abstract] [Full Text] [Related]
12. Targeting Protein Interaction Hotspots Using Structured and Disordered Chimeric Peptide Inhibitors.
Mayer G; Shpilt Z; Kowalski H; Tshuva EY; Friedler A
ACS Chem Biol; 2022 Jul; 17(7):1811-1823. PubMed ID: 35758642
[TBL] [Abstract] [Full Text] [Related]
13. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in ovarian cancer Patients.
Zavarikina TM; Khokhlova SV; Tyulyandina AS; Khabas GN; Asaturova AV; Nosova YV; Brenner PK; Kapralova MA; Khodirev DS; Stenina MB
Bull Exp Biol Med; 2021 Oct; 171(6):755-759. PubMed ID: 34709513
[TBL] [Abstract] [Full Text] [Related]
14. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/mdm2 Inhibitor.
Lai ZY; Tsai KY; Chang SJ; Chuang YJ
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
[TBL] [Abstract] [Full Text] [Related]
15. mdm2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas.
Shetty S; Habeeb O; Rivera C; Astbury C; Przybycin C; Joehlin-Price AS
Hum Pathol; 2021 Nov; 117():42-50. PubMed ID: 34391746
[TBL] [Abstract] [Full Text] [Related]
16. Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.
Valenciaga A; Iwenofu OH; Tinoco G
J Natl Compr Canc Netw; 2021 Jul; 19(7):775-779. PubMed ID: 34340207
[TBL] [Abstract] [Full Text] [Related]
17. ITPKA induces cell senescence, inhibits ovarian cancer tumorigenesis and can be downregulated by miR-203.
Shaosheng W; Shaochuang W; Lichun F; Na X; Xiaohong Z
Aging (Albany NY); 2021 Apr; 13(8):11822-11832. PubMed ID: 33879633
[TBL] [Abstract] [Full Text] [Related]
18. Impact of
Helwa R; Gansmo LB; Bjørnslett M; Halle MK; Werner HMJ; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
Biomarkers; 2021 Jun; 26(4):302-308. PubMed ID: 33645339
[TBL] [Abstract] [Full Text] [Related]
19. Role of TSC1 in physiology and diseases.
Mallela K; Kumar A
Mol Cell Biochem; 2021 Jun; 476(6):2269-2282. PubMed ID: 33575875
[TBL] [Abstract] [Full Text] [Related]
20. Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous ovarian Adenocarcinoma.
Kutilin DS; Tsandekova MR; Porkhanova NV
Bull Exp Biol Med; 2021 Jan; 170(3):332-339. PubMed ID: 33452985
[TBL] [Abstract] [Full Text] [Related]
[Next]
